A practical reference on peptide fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-11 and is reviewed periodically as new material appears.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Rongliflozin/Olorigliflozin has been evaluated in phase I trials, but is not yet approved by the FDA Sergliflozin etabonate discontinued after phase II trials. Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Tofogliflozin, developed by Sanofi and Kowa Pharmaceutical, was approved in Japan in March 2014, under the brand names Apleway and Deberza. Velagliflozin, marketed as Senvelgo, produced by Boehringer Ingelheim Animal Health, was approved for use in diabetic cats in 2023.
=== History === The lineage of the 1st Transportation Detachment, 2nd Mobile Corps dates back to the 2nd World War, when it was known as the Laiyuan guerilla detachment of the Jin-Cha-Ji Military district. It participated in the Chinese civil war, WW2 and the Korean war. After becoming part of the PLA Basic Engineering Corps it was deployed to build the Duku Highway in 1974 in which 47 personnel lost their lives. Prior to 1984, the transportation corps was part of the People's Liberation Army Basic Engineering Corps. The 7th Transportation Detachment assisted in disaster relief after the 2015 Tianjin explosions. The 6th Detachment of the transportation corps deployed 105 officers and 48 vehicles for urban search and rescue duties during the 2015 Shenzhen landslide.
==== Ovarian function ==== In 2021, a phase I non-randomized clinical trial, the first in humans, evaluated the safety and potential benefits of injecting autologous adipose-derived stem cells (ADSCs) into the ovaries of women with premature ovarian failure (POF). Nine patients received varying doses of ADSCs (5, 10, or 15 million cells), and were followed for up to 12 months. The results showed that there were no serious side effects reported, menstruation resumed in 4 out of 9 patients, serum FSH levels decreased in 4 patients, indicating some hormonal improvement. Additionally, ovarian volume, AMH, and antral follicle count (AFC) showed variable results with no significant differences between groups. The study concluded that intra-ovarian ADSC therapy appears safe and feasible, with some signs of improved ovarian function, though results were inconsistent. Larger randomized trials are needed for confirmation.
Sources: en.wikipedia.org
=== Natural dye === Recent research shows both leaves and seeds from Ginkgo biloba plants can be used as a natural (yellow or yellowish) dye on wool, silk or other protein fibre textiles. The plant's chemistry seems to also add anti-microbial properties to the fabric.
AMP → IMP → Inosine → Hypoxanthine → Xanthine → Uric acid Hyperammonemia is also seen post-exercise in McArdle disease (GSD-V) and phosphoglucomutase deficiency (PGM1-CDG, formerly GSD-XIV), due to the purine nucleotide cycle running when the ATP reservoir is low due to the glycolytic block.AMP + H2O + H+ → IMP + NH3
(See also: Bangladesh–United States relations#History) Later in 1974, India conducted its first nuclear test, Smiling Buddha, which was opposed by the US, however it also concluded that the test did not violate any agreement and proceeded with a June 1974 shipment of enriched uranium for the Tarapur reactor. In the late 1970s, with the Janata Party leader Morarji Desai becoming the prime minister, India improved its relations with the US, led by Jimmy Carter, despite the latter signing an order in 1978 barring nuclear material from being exported to India due to India's non-proliferation record. Despite the return of Indira Gandhi to power in 1980, the relations between the two countries continued to improve gradually, although India did not support the United States in its role in the Soviet invasion and occupation of Afghanistan. Indian Foreign Minister P. V. Narasimha Rao expressed "grave concern" over the United States's decision to "rearm" Pakistan; the two countries were working closely together to counter the Soviets in Afghanistan. The Reagan administration led by US President Ronald Reagan provided limited assistance to India. India sounded out Washington on the purchase of a range of US defence technology, including F-5 aircraft, super computers, night vision goggles and radars. In 1984, Washington approved the supply of selected technology to India including gas turbines for naval frigates and engines for prototypes for India's light combat aircraft.
Sources: en.wikipedia.org
Glycoprotein hormones, alpha polypeptide is a protein that in humans is encoded by the CGA gene. Thyroid-stimulating hormone (TSH) and the gonadotropin hormones human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) are heterodimers consisting of alpha and beta subunits (also called chains) that are associated non-covalently. The alpha subunits of these four human glycoprotein hormones are identical; however, their beta chains are unique and confer biological specificity. The protein encoded by this gene is the alpha subunit and belongs to the glycoprotein hormones alpha chain family. CGA levels are regulated by ELAVL1/HuR, and the small molecule Eltrombopag, which targets HuR/RNA interactions, has been shown to reduce CGA levels in human cultured cells.
Jan Jozef van Deemter (31 March 1918 – 10 October 2004) was a Dutch physicist and engineer known for the Van Deemter equation in chromatography. He obtained his doctorate in physics from the University of Amsterdam in June of 1950. Starting in 1947 he began work for Royal Dutch Shell as a researcher and it was there that he developed and published his article in 1956.
Wolfberries are most often sold in dried form. When ripe, the oblong, red berries are tender and must be picked or shaken from the vine into trays to avoid spoiling. The fruits are preserved by drying them in full sun on open trays or by mechanical dehydration, employing a progressively increasing series of heat exposure over 48 hours.
This test should not be performed on children outside a specialist pediatric endocrine unit. Ischemic heart disease Epilepsy Severe panhypopituitarism, hypoadrenalism Hypothyroidism impairs the GH and cortisol response. Patients should have corticosteroid replacement commenced prior to thyroxine as the latter has been reported to precipitate an Addisonian crisis with dual deficiency. If adrenal insufficiency is confirmed, the need for a repeat ITT may need to be reconsidered after 3 months thyroxine therapy.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.